BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Anulex Technologies, Inc. to Raise a Minimum of $20 Million in Series E Financing


6/3/2010 1:42:14 PM

MINNEAPOLIS--(BUSINESS WIRE)--Anulex Technologies, Inc., a privately held medical device manufacturer focusing on soft tissue Preservation & Anular RepairTM products, announced the first closing of its fifth round of private equity financing which will total a minimum of $20 million. The Series E round was led by a new unnamed strategic investor with participation from existing investors Affinity Capital, Delphi Ventures, MB Venture Partners, New Enterprise Associates, SightLine Partners and Split Rock Partners. In addition, another new investor - the Hatteras Late Stage VC Fund 1, L.P. joined the Series E financing round.

Commenting on the financing, Rich Lunsford, Anulex’s President and Chief Executive Officer, said, “We are excited to complete this round of financing during a very challenging funding environment. This financing will give us the ability to expand our commercialization efforts and complete the follow-up phases of our ground-breaking XcloseTM Tissue Repair System post market clinical study. The study represents one of the largest prospective randomized clinical studies in spine with the goal of providing further evidence to support the benefits of preservation and repair of the anulus. This funding will also provide additional investment for a feasibility study for our RimcloseTM product and further support the company’s innovative research and development strategy. We are very enthused to have a new strategic investor join our world class investor group and we believe there may be opportunities to collaborate with each other in the future”

About Anulex

Anulex Technologies, Inc. is a privately held company dedicated to the development and commercialization of unique and proprietary soft tissue repair products. Back pain afflicts four out of every five individuals at some point during their life, and it is a major cause of disability. Once the Series E financing is completed, Anulex will have raised approximately $68.6 million through five rounds of equity financing to support these efforts. More information on the Company can be found at www.anulex.com.

Xclose, Rimclose, Anulex, and Preservation & Anular Repair are trademarks of Anulex Technologies, Inc.

Contacts

Anulex Technologies, Inc.

David Noel, 952-224-4017

Vice President of Finance and CFO

dnoel@anulex.com

Read at BioSpace.com
Read at News Release


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->